Search hospitals > Utah > Salt Lake City
Primary Children's Hospital
Claim this profileSalt Lake City, Utah 84113
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Brain Tumor
Conducts research for Neuroblastoma
412 reported clinical trials
32 medical researchers
Summary
Primary Children's Hospital is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Brain Tumor, Neuroblastoma and other specialties. Primary Children's Hospital is involved with conducting 412 clinical trials across 600 conditions. There are 32 research doctors associated with this hospital, such as Matthew Dietz, Luke D. Maese, Michael Pulsipher, MD, and Priya Chan.Area of expertise
1Leukemia
Global LeaderStage II
NTRK1 positive
NTRK positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Matthew DietzPrimary Children's Hospital7 years of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
32 reported clinical trials
61 drugs studied
Luke D. MaesePrimary Children's Hospital4 years of reported clinical research
Studies Brain Tumor
Studies Leukemia
23 reported clinical trials
56 drugs studied
Michael Pulsipher, MDChildren's Hospital Los Angeles5 years of reported clinical research
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
16 reported clinical trials
31 drugs studied
Priya ChanPrimary Children's Hospital2 years of reported clinical research
Studies Brain Tumor
Studies Astrocytoma
9 reported clinical trials
20 drugs studied
Clinical Trials running at Primary Children's Hospital
Brain Tumor
Osteosarcoma
Germ Cell Tumors
Lymphoma
Non-Hodgkin's Lymphoma
Langerhans Cell Histiocytosis
Tumors
Rhabdomyosarcoma
Rhabdoid Tumor
Astrocytoma
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Selumetinib vs Carboplatin/Vincristine
for Brain Cancer
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.
Recruiting2 awards Phase 328 criteria
Selumetinib + Vinblastine
for Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Recruiting2 awards Phase 339 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Primary Children's Hospital?
Primary Children's Hospital is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Brain Tumor, Neuroblastoma and other specialties. Primary Children's Hospital is involved with conducting 412 clinical trials across 600 conditions. There are 32 research doctors associated with this hospital, such as Matthew Dietz, Luke D. Maese, Michael Pulsipher, MD, and Priya Chan.
Where is Primary Children's Hospital located?
**Primary Children's Hospital**
- **Address:** 100 Mario Capecchi Drive, Salt Lake City, UT 84113.
- **Public Transportation:** Accessible by public transportation. The nearest light rail station is University South Campus Station, approximately a 17-minute walk away.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Primary Children's Hospital, please use the following contact information:
- **Financial Assistance:** (614) 722-2070
- **Hospital Care Assurance Program (HCAP):** (614) 722-2055, for individuals with income below 100% of the poverty level who are not eligible for Medicaid.
- **Healthy Start and Healthy Families:** (614) 722-6855, providing free or low-cost health care coverage to families, children under age 19, and pregnant women.
- **Customer Service for Billing and Insurance:** (614) 722-2055
What insurance does Primary Children's Hospital accept?
Primary Children's Hospital accepts a wide range of insurance plans, including Medicaid/Children's Health Insurance Program (CHIP). Accepted insurance providers include Aetna, AmeriHealth, Cigna, Empire Blue Cross, Horizon BCBS, Oxford Health Plans, United Health Care, and more. For behavioral health services, the hospital accepts SelectHealth, EMI, PEHP, DMBA, and BCBS. It is advised to contact the hospital or your insurance provider to confirm specific coverage details.
What awards or recognition has Primary Children's Hospital received?
Primary Children's Hospital, located in Salt Lake City, Utah, has been awarded Magnet Recognition, the highest national honor for nursing excellence, by the American Nurses Credentialing Center's Magnet Recognition Program®. This prestigious award underscores the hospital's dedication to exceptional patient care, nursing professionalism, and effective teamwork. Furthermore, the hospital partners with the University of Utah School of Medicine to conduct pediatric research, notably in the University Child Abuse Recognition & Education program.